L’évolution du pouvoir d’achat immobilier selon l’âge des ménagesMonimmeuble.com
L’Université Paris-Dauphine et le Crédit Foncier publient une étude consacrée à l’évolution du pouvoir d’achat immobilier selon l’âge des ménages dans les grandes villes françaises. Trois années d’observation (celles de l’enquête patrimoine de l’INSEE) ont été retenues : 1998, 2004 et 2010.
http://creditfoncier.com/
Les résidences-seniors offrent un logement et des services adaptés aux personnes âgées, dont le profil et les besoins ont évolué au cours du temps. Le besoin est d’ores et déjà présent ; on compte actuellement cinq millions de plus de 75 ans dans leur domicile, dont une part notable est confrontée au problème de la perte d’autonomie.
www.ehpa.fr
DCN Diagnostics. Design and Development of Lateral Flow Assay SystemsBrendan O'Farrell
DCN Diagnostics designs and develops rapid assay systems for medical and veterinary diagnostics, bio-defense, agriculture, environmental testing and other market segments. DCN's service offering includes contract assay development, education and training courses in lateral flow technologies, industrial design and mechanical engineering services related to development of related devices for rapid diagnostics. Our specialties include lateral flow, flow through and microfluidic assay formats, and we have developed qualitative, quantitative, visual or fluorescent assay systems. DCN's ISO 9001:228 and EN 13485 compliant quality system is set up to allow us to deliver the full FDA compliant design history file. Our process and unique teams of highly experienced development scientists working alongside our engineering teams allow us to deliver the product, not just the parts. DCN Diagnostics is the sole supplier of cellulose nanobead technology for lateral flow diagnostics outside of Japan and can supply technical consulting and development assistance to companies wishing to develop and manufacture highly sensitive and quantitative lateral flow assays using the NanoAct (tm) beads. Our experience in multiplexing and joint ownership in the Symbolics patents covering aspects of multipex arraying in lateral flow formats allows DCN to assist our clients in creating highly unique and functional assays for any environment or application. DCN also provides our unique UltraGold (tm) colloidal gold for use in lateral flow assays. DCN's 40nm gold colloid is highly controlled, very stable and designed specifically for use in lateral flow and flow through assays.
Charte de Paris pour l’Accessibilité universelle de l’APAJHMonimmeuble.com
Point d’orgue de notre réflexion collective, le mouvement APAJH a adopté à l’unanimité, le 21 juin dernier, la Charte de Paris pour l’Accessibilité universelle. Cette charte propose une feuille de route dont l’ambition est de garantir l’accès à tout, pour tous, dans tous les domaines de la vie.
http://apajh.org/
Lateral flow assays are the most robust, mature immuno sensor available today. Performance in some applications has historically been limited by difficulties in multiplexing and quantification. Novel approaches have been developed and commercialized in recent years that allow for the development and manufacturing of highly multiplexed arrays in lateral flow assays. The patented Symbolics (tm) approach is one such methodology. Symboics (tm) allows for the creation of arrays in lateral flow fields that develop evenly, allowing in turn for the creation of highly complex features such as letters and symbols and also allows for creation of multiplex assays with advanced features such as internal controls. This presentation introduces the principles of multiplexed arraying and the Symbolics technology
Design and development of lateral flow assays for field useBrendan O'Farrell
Lateral flow assays are the most mature, stable, field deployable sensor available today. They can be used in myriad applications, from medical diagnostics to veterinary testing, agriculture, bio-defense, food testing and environmental testing, to name a few. Performance of these assays has evolved to the point where they can equal that of much more highly complex laboratory based diagnostic test formats. They can be quantitative, multiplexed and highly sensitive if developed and manufactured correctly. Design and development of these high performance lateral flow systems requires a from-first-principles approach, with an eye to optimizing the system for reproduciblity and sensitivity. Employing user - centered design and development practices greatly improves the odds of successful commercialization. DCN Diagnostics (formerly Diagnostic Consulting Network) develops high performance lateral flow assay systems for use in any environment. Our concurrent design and development process, employing cross functional teams of industrial design and mechanical engineers alongside our immunoassay development teams, ensures that the right product is developed the right way to allow for most efficient regulatory approval and commercialization. Our development process is fully design controlled and operates under our ISO 9001:2008 and EN 13485 compliant quality system. With literally hundreds of assays developed, and transferred to manufacturing, DCN is the go-to supplier of contract development services in the point of care diagnostic test market. Additionally, our consulting teams can provide a deep strategic vision to our clients, assisting in all aspects of product development and commercialization, including regulatory affairs and clinical trial management. This presentation describes DCN's development process and illustrates the benefit of a user centered design process in creating the right rapid assay for your market, focusing on field deployed tests for clinical diagnostics, veterinary testing and bio-defense applications. A variety of case studies are shown, illustrating the principles discussed.
L’évolution du pouvoir d’achat immobilier selon l’âge des ménagesMonimmeuble.com
L’Université Paris-Dauphine et le Crédit Foncier publient une étude consacrée à l’évolution du pouvoir d’achat immobilier selon l’âge des ménages dans les grandes villes françaises. Trois années d’observation (celles de l’enquête patrimoine de l’INSEE) ont été retenues : 1998, 2004 et 2010.
http://creditfoncier.com/
Les résidences-seniors offrent un logement et des services adaptés aux personnes âgées, dont le profil et les besoins ont évolué au cours du temps. Le besoin est d’ores et déjà présent ; on compte actuellement cinq millions de plus de 75 ans dans leur domicile, dont une part notable est confrontée au problème de la perte d’autonomie.
www.ehpa.fr
DCN Diagnostics. Design and Development of Lateral Flow Assay SystemsBrendan O'Farrell
DCN Diagnostics designs and develops rapid assay systems for medical and veterinary diagnostics, bio-defense, agriculture, environmental testing and other market segments. DCN's service offering includes contract assay development, education and training courses in lateral flow technologies, industrial design and mechanical engineering services related to development of related devices for rapid diagnostics. Our specialties include lateral flow, flow through and microfluidic assay formats, and we have developed qualitative, quantitative, visual or fluorescent assay systems. DCN's ISO 9001:228 and EN 13485 compliant quality system is set up to allow us to deliver the full FDA compliant design history file. Our process and unique teams of highly experienced development scientists working alongside our engineering teams allow us to deliver the product, not just the parts. DCN Diagnostics is the sole supplier of cellulose nanobead technology for lateral flow diagnostics outside of Japan and can supply technical consulting and development assistance to companies wishing to develop and manufacture highly sensitive and quantitative lateral flow assays using the NanoAct (tm) beads. Our experience in multiplexing and joint ownership in the Symbolics patents covering aspects of multipex arraying in lateral flow formats allows DCN to assist our clients in creating highly unique and functional assays for any environment or application. DCN also provides our unique UltraGold (tm) colloidal gold for use in lateral flow assays. DCN's 40nm gold colloid is highly controlled, very stable and designed specifically for use in lateral flow and flow through assays.
Charte de Paris pour l’Accessibilité universelle de l’APAJHMonimmeuble.com
Point d’orgue de notre réflexion collective, le mouvement APAJH a adopté à l’unanimité, le 21 juin dernier, la Charte de Paris pour l’Accessibilité universelle. Cette charte propose une feuille de route dont l’ambition est de garantir l’accès à tout, pour tous, dans tous les domaines de la vie.
http://apajh.org/
Lateral flow assays are the most robust, mature immuno sensor available today. Performance in some applications has historically been limited by difficulties in multiplexing and quantification. Novel approaches have been developed and commercialized in recent years that allow for the development and manufacturing of highly multiplexed arrays in lateral flow assays. The patented Symbolics (tm) approach is one such methodology. Symboics (tm) allows for the creation of arrays in lateral flow fields that develop evenly, allowing in turn for the creation of highly complex features such as letters and symbols and also allows for creation of multiplex assays with advanced features such as internal controls. This presentation introduces the principles of multiplexed arraying and the Symbolics technology
Design and development of lateral flow assays for field useBrendan O'Farrell
Lateral flow assays are the most mature, stable, field deployable sensor available today. They can be used in myriad applications, from medical diagnostics to veterinary testing, agriculture, bio-defense, food testing and environmental testing, to name a few. Performance of these assays has evolved to the point where they can equal that of much more highly complex laboratory based diagnostic test formats. They can be quantitative, multiplexed and highly sensitive if developed and manufactured correctly. Design and development of these high performance lateral flow systems requires a from-first-principles approach, with an eye to optimizing the system for reproduciblity and sensitivity. Employing user - centered design and development practices greatly improves the odds of successful commercialization. DCN Diagnostics (formerly Diagnostic Consulting Network) develops high performance lateral flow assay systems for use in any environment. Our concurrent design and development process, employing cross functional teams of industrial design and mechanical engineers alongside our immunoassay development teams, ensures that the right product is developed the right way to allow for most efficient regulatory approval and commercialization. Our development process is fully design controlled and operates under our ISO 9001:2008 and EN 13485 compliant quality system. With literally hundreds of assays developed, and transferred to manufacturing, DCN is the go-to supplier of contract development services in the point of care diagnostic test market. Additionally, our consulting teams can provide a deep strategic vision to our clients, assisting in all aspects of product development and commercialization, including regulatory affairs and clinical trial management. This presentation describes DCN's development process and illustrates the benefit of a user centered design process in creating the right rapid assay for your market, focusing on field deployed tests for clinical diagnostics, veterinary testing and bio-defense applications. A variety of case studies are shown, illustrating the principles discussed.